UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 6,
2023
Anzu Special Acquisition Corp I
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction
of incorporation)
|
|
001-40133
(Commission
File Number)
|
|
86-1369123
(IRS Employer
Identification No.)
|
12610 Race Track Road, Suite 250
Tampa, FL
(Address of principal executive offices)
|
|
33626
(Zip Code)
|
Registrant’s telephone number, including area code: (202)
742-5870
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
x |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbols |
|
Name of each exchange on
which registered |
Units,
each consisting of one share of Class A Common Stock and one-third
of one redeemable Warrant |
|
ANZUU |
|
The
Nasdaq Stock Market LLC |
Class
A Common Stock, par value $0.0001 per share |
|
ANZU |
|
The
Nasdaq Stock Market LLC |
Redeemable
Warrants, each whole Warrant exercisable for one share of Class A
Common Stock at an exercise price of $11.50 per
share |
|
ANZUW |
|
The
Nasdaq Stock Market LLC |
Indicate by check mark
whether the registrant is an emerging growth company as defined in
Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of
this chapter).
Emerging
growth company x
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ¨
Item 8.01. Other Events.
The management of Anzu Special Acquisition Corp I (“Anzu”) is
grateful for the continued inbound interest in the potential
business combination (the “Proposed Business Combination”)
referenced in Anzu’s definitive proxy statement, filed
with the Securities and Exchange Commission (“SEC”) on January 20,
2023 (the “Extension Proxy Statement”) for a special meeting of
stockholders (the “Stockholder Meeting”) to be held to vote on the
proposal to amend Anzu’s amended and restated certificate of
incorporation (the “Charter”) to extend the date by which Anzu has
to consummate an initial business combination from March 4, 2023 to
September 30, 2023 or such earlier date as determined by Anzu’s
board of directors (the “Extension Amendment Proposal”).
As noted in the Extension Proxy Statement:
“Anzu has entered into a letter of intent regarding a business
combination with a US-based medical device company that has
developed and is in early clinical testing of an implanted device
that already received “Breakthrough Device Designation” from the
Food and Drug Administration. Anzu currently expects to file
definitive agreements in February 2023, execute the definitive
documents shortly following the Stockholder Meeting and close in
the first half of 2023. The letter of intent contains certain
conditions to the closing of the business combination, including
but not limited to Anzu having more than $40.0 million in the Trust
Account (as defined below) immediately prior to any redemptions at
the closing of the business combination. There can be no assurance
Anzu will execute definitive agreements or close on the timeline
currently expected or at all.”
Attached hereto as Exhibit 99.1 and incorporated herein by
reference is an investor presentation which provides an overview of
Envoy Medical Corporation (“Envoy”), the target of the Proposed
Business Combination, and further assists stockholders in
understanding the Proposed Business Combination. On January 30,
2023, Anzu and Envoy extended their mutual exclusivity to work
towards the Proposed Business Combination until March 4, 2023. The
Nasdaq Stock Market LLC has reserved the stock symbol of “COCH”
(referring to Envoy’s planned cochlear implant) for the prospective
combined company.
Anzu management continues to work with stockholders, legal
advisors, accounting advisors, and other stakeholders to complete
the Extension Amendment Proposal and Proposed Business
Combination.
Forward-Looking Statements
This Current Report on Form 8-K includes “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the United States Private Securities Litigation Reform Act of 1995.
Forward-Looking statements may be identified by the use of words
such as “estimate,” “plan,” “project,” “forecast,” “intend,”
“will,” “expect,” “anticipate,” “believe,” “seek,” “target” or
other similar expressions that predict or indicate future events or
trends or that are not statements of historical matters, but the
absence of these words does not mean that a statement is not
forward-looking. Such statements may include, but are not limited
to, statements regarding the Stockholder Meeting and the Proposed
Business Combination. The forward-looking statements contained in
this Current Report on Form 8-K reflect Anzu’s current views about
future events and are subject to numerous known and unknown risks,
uncertainties, assumptions and changes in circumstances that may
cause its actual results to differ significantly from those
expressed in any forward-looking statement. Anzu does not guarantee
that the transactions and events described will happen as described
(or that they will happen at all). These forward-looking statements
are subject to a number of risks and uncertainties, including, but
not limited to, changes in domestic and foreign business, market,
financial, political, and legal conditions; the failure of Anzu to
obtain the requisite approvals for the Extension Amendment
Proposal; the amount of redemptions by Anzu’s public stockholders
in connection with the Stockholder Meeting and the Proposed
Business Combination; the inability of the parties to enter into a
definitive agreement relating to a business combination on the
timeline discussed herein or at all; the inability of the parties
to successfully or timely consummate the Proposed Business
Combination, including the risk that any required regulatory
approvals are not obtained, are delayed or are subject to
unanticipated conditions that could adversely affect the combined
company or the expected benefits of the Proposed Business
Combination or that the approval of stockholders is not obtained;
failure to realize the anticipated benefits of the Proposed
Business Combination; and other risks and uncertainties set forth
in the section entitled “Risk Factors” in the Extension Proxy
Statement, in Anzu’s Annual Report on Form 10-K for the year ended
December 31, 2021, as filed with the SEC on March 31, 2022 and in
other reports Anzu files with the SEC. If any of these risks
materialize or Anzu’s assumptions prove incorrect, actual results
could differ materially from the results implied by these
forward-looking statements. While forward-looking statements
reflect Anzu’s good faith beliefs, they are not guarantees of
future performance. Anzu disclaims any obligation to publicly
update or revise any forward-looking statement to reflect changes
in underlying assumptions or factors, new information, data or
methods, future events or other changes after the date of this
Current Report on Form 8-K, except as required by applicable law.
You should not place undue reliance on any forward-looking
statements, which are based only on information currently available
to Anzu.
Additional Information and Where to Find It
In connection with the Proposed Business Combination, Anzu and
Envoy intend to prepare, and Anzu intends to file a registration
statement on Form S-4 (the “Registration Statement”) containing a
proxy statement/prospectus and certain other related documents,
which will be both the proxy statement to be distributed to Anzu’s
stockholders in connection with Anzu’s solicitation of proxies for
the vote by Anzu’s stockholders with respect to the Proposed
Business Combination and other matters as may be described in the
Registration Statement, as well as the prospectus relating to the
offer and sale of the securities to be issued in connection with
the Proposed Business Combination. When available, Anzu will mail
the definitive proxy statement/prospectus and other relevant
documents to its stockholders as of a record date to be established
for voting on the Proposed Business Combination. This Current
Report on Form 8-K is not a substitute for the Registration
Statement, the definitive proxy statement/prospectus or any other
document that Anzu will send to its stockholders in connection with
the Proposed Business Combination. Investors and security holders
are urged to read, when available, the preliminary proxy
statement/prospectus in connection with Anzu’s solicitation of
proxies for its special meeting of stockholders to be held to
approve the Proposed Business Combination (and related matters) and
general amendments thereto and the definitive proxy
statement/prospectus because the proxy statement/prospectus will
contain important information about the Proposed Business
Combination and the parties to the Proposed Business
Combination.
Copies of the preliminary proxy statement/prospectus, the
definitive proxy statement/prospectus and other documents filed by
Anzu or Envoy with the SEC may be obtained, once available, free of
charge at the SEC’s website at www.sec.gov.
Participants in the Solicitation
Anzu and its directors, executive officers, other members of
management, and employees, under SEC rules, may be deemed to be
participants in the solicitation of proxies of Anzu’s stockholders
in connection with the Proposed Business Combination. Information
regarding the persons who may, under SEC rules, be deemed
participants in the solicitation of Anzu’s stockholders in
connection with the Proposed Business Combination will be in the
Registration Statement, including a proxy statement/prospectus,
when it is filed with the SEC. Investors and security holders may
obtain more detailed information regarding the names and interests
in the Proposed Business Combination of Anzu’s directors and
officers in Anzu’s filings with the SEC and such information will
also be in the Registration Statement to be filed with the SEC,
which will include the proxy statement/prospectus of Anzu for the
Proposed Business Combination. These documents can be obtained free
of charge at the SEC’s website at www.sec.gov.
Envoy and its directors and executive officers may also be deemed
to be participants in the solicitation of proxies from the
stockholders of Anzu in connection with the Proposed Business
Combination. A list of the names of such directors and executive
officers and information regarding their interests in the Proposed
Business Combination will be included in the proxy
statement/prospectus for the Proposed Business Combination when
available.
No Offer or Solicitation
This Current Report on Form 8-K relates to the Proposed Business
Combination and is neither an offer to purchase, nor a solicitation
of an offer to sell, subscribe for or buy any securities or the
solicitation of any vote in any jurisdiction pursuant to the
Proposed Business Combination or otherwise, nor shall there be any
sale, issuance or transfer or securities in any jurisdiction in
contravention of applicable law. No offer of securities shall be
made except by means of a prospectus meeting the requirements of
Section 10 of the Securities Act of 1933, or an exemption
therefrom, and otherwise in accordance with applicable law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, hereunto duly authorized.
Dated: February 6, 2023
|
Anzu Special
Acquisition Corp I |
|
|
|
By: |
/s/ Dr. Whitney Haring-Smith |
|
|
Dr. Whitney Haring-Smith
Chief Executive Officer
|
Anzu Special Acquisition... (NASDAQ:ANZU)
Historical Stock Chart
From May 2023 to Jun 2023
Anzu Special Acquisition... (NASDAQ:ANZU)
Historical Stock Chart
From Jun 2022 to Jun 2023